Cargando…

Epimedin C Alleviates Glucocorticoid-Induced Suppression of Osteogenic Differentiation by Modulating PI3K/AKT/RUNX2 Signaling Pathway

Secondary osteoporosis is triggered mostly by glucocorticoid (GC) therapy. Dexamethasone (DEX) was reported to inhibit osteogenic differentiation in zebrafish larvae and MC3T3-E1 cells in prior research. In this research, we primarily examined the protective impacts of epimedin C on the osteogenic i...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Yongxiang, Chen, Shichun, Huang, Linxuan, Han, Weichao, Shao, Yingying, Chen, Minyi, Zhang, Yusheng, He, Ruirong, Xie, Baocheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9291512/
https://www.ncbi.nlm.nih.gov/pubmed/35860032
http://dx.doi.org/10.3389/fphar.2022.894832
_version_ 1784749152419184640
author Xu, Yongxiang
Chen, Shichun
Huang, Linxuan
Han, Weichao
Shao, Yingying
Chen, Minyi
Zhang, Yusheng
He, Ruirong
Xie, Baocheng
author_facet Xu, Yongxiang
Chen, Shichun
Huang, Linxuan
Han, Weichao
Shao, Yingying
Chen, Minyi
Zhang, Yusheng
He, Ruirong
Xie, Baocheng
author_sort Xu, Yongxiang
collection PubMed
description Secondary osteoporosis is triggered mostly by glucocorticoid (GC) therapy. Dexamethasone (DEX) was reported to inhibit osteogenic differentiation in zebrafish larvae and MC3T3-E1 cells in prior research. In this research, we primarily examined the protective impacts of epimedin C on the osteogenic inhibition impact of MC3T3-E1 cells and zebrafish larvae mediated by DEX. The findings illustrated no apparent toxicity for MC3T3-E1 cells after administering epimedin C at increasing dosages from 1 to 60 μM and no remarkable proliferation in MC3T3-E1 cells treated using DEX. In MC3T3-E1 cells that had been treated using DEX, we discovered that epimedin C enhanced alkaline phosphatase activities and mineralization. Epimedin C could substantially enhance the protein expression of osterix (OSX), Runt-related transcription factor 2 (RUNX2), and alkaline phosphatase (ALPL) in MC3T3-E1 cells subjected to DEX treatment. Additionally, epimedin C stimulated PI3K and AKT signaling pathways in MC3T3-E1 cells that had been treated using DEX. Furthermore, in a zebrafish larvae model, epimedin C was shown to enhance bone mineralization in DEX-mediated bone impairment. We also found that epimedin C enhanced ALPL activity and mineralization in MC3T3-E1 cells treated using DEX, which may be reversed by PI3K inhibitor (LY294002). LY294002 can also reverse the protective impact of epimedin C on DEX-mediated bone impairment in zebrafish larval. These findings suggested that epimedin C alleviated the suppressive impact of DEX on the osteogenesis of zebrafish larval and MC3T3-E1 cells via triggering the PI3K and AKT signaling pathways. Epimedin C has significant potential in the development of innovative drugs for the treatment of glucocorticoid-mediated osteoporosis.
format Online
Article
Text
id pubmed-9291512
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-92915122022-07-19 Epimedin C Alleviates Glucocorticoid-Induced Suppression of Osteogenic Differentiation by Modulating PI3K/AKT/RUNX2 Signaling Pathway Xu, Yongxiang Chen, Shichun Huang, Linxuan Han, Weichao Shao, Yingying Chen, Minyi Zhang, Yusheng He, Ruirong Xie, Baocheng Front Pharmacol Pharmacology Secondary osteoporosis is triggered mostly by glucocorticoid (GC) therapy. Dexamethasone (DEX) was reported to inhibit osteogenic differentiation in zebrafish larvae and MC3T3-E1 cells in prior research. In this research, we primarily examined the protective impacts of epimedin C on the osteogenic inhibition impact of MC3T3-E1 cells and zebrafish larvae mediated by DEX. The findings illustrated no apparent toxicity for MC3T3-E1 cells after administering epimedin C at increasing dosages from 1 to 60 μM and no remarkable proliferation in MC3T3-E1 cells treated using DEX. In MC3T3-E1 cells that had been treated using DEX, we discovered that epimedin C enhanced alkaline phosphatase activities and mineralization. Epimedin C could substantially enhance the protein expression of osterix (OSX), Runt-related transcription factor 2 (RUNX2), and alkaline phosphatase (ALPL) in MC3T3-E1 cells subjected to DEX treatment. Additionally, epimedin C stimulated PI3K and AKT signaling pathways in MC3T3-E1 cells that had been treated using DEX. Furthermore, in a zebrafish larvae model, epimedin C was shown to enhance bone mineralization in DEX-mediated bone impairment. We also found that epimedin C enhanced ALPL activity and mineralization in MC3T3-E1 cells treated using DEX, which may be reversed by PI3K inhibitor (LY294002). LY294002 can also reverse the protective impact of epimedin C on DEX-mediated bone impairment in zebrafish larval. These findings suggested that epimedin C alleviated the suppressive impact of DEX on the osteogenesis of zebrafish larval and MC3T3-E1 cells via triggering the PI3K and AKT signaling pathways. Epimedin C has significant potential in the development of innovative drugs for the treatment of glucocorticoid-mediated osteoporosis. Frontiers Media S.A. 2022-07-04 /pmc/articles/PMC9291512/ /pubmed/35860032 http://dx.doi.org/10.3389/fphar.2022.894832 Text en Copyright © 2022 Xu, Chen, Huang, Han, Shao, Chen, Zhang, He and Xie. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Xu, Yongxiang
Chen, Shichun
Huang, Linxuan
Han, Weichao
Shao, Yingying
Chen, Minyi
Zhang, Yusheng
He, Ruirong
Xie, Baocheng
Epimedin C Alleviates Glucocorticoid-Induced Suppression of Osteogenic Differentiation by Modulating PI3K/AKT/RUNX2 Signaling Pathway
title Epimedin C Alleviates Glucocorticoid-Induced Suppression of Osteogenic Differentiation by Modulating PI3K/AKT/RUNX2 Signaling Pathway
title_full Epimedin C Alleviates Glucocorticoid-Induced Suppression of Osteogenic Differentiation by Modulating PI3K/AKT/RUNX2 Signaling Pathway
title_fullStr Epimedin C Alleviates Glucocorticoid-Induced Suppression of Osteogenic Differentiation by Modulating PI3K/AKT/RUNX2 Signaling Pathway
title_full_unstemmed Epimedin C Alleviates Glucocorticoid-Induced Suppression of Osteogenic Differentiation by Modulating PI3K/AKT/RUNX2 Signaling Pathway
title_short Epimedin C Alleviates Glucocorticoid-Induced Suppression of Osteogenic Differentiation by Modulating PI3K/AKT/RUNX2 Signaling Pathway
title_sort epimedin c alleviates glucocorticoid-induced suppression of osteogenic differentiation by modulating pi3k/akt/runx2 signaling pathway
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9291512/
https://www.ncbi.nlm.nih.gov/pubmed/35860032
http://dx.doi.org/10.3389/fphar.2022.894832
work_keys_str_mv AT xuyongxiang epimedincalleviatesglucocorticoidinducedsuppressionofosteogenicdifferentiationbymodulatingpi3kaktrunx2signalingpathway
AT chenshichun epimedincalleviatesglucocorticoidinducedsuppressionofosteogenicdifferentiationbymodulatingpi3kaktrunx2signalingpathway
AT huanglinxuan epimedincalleviatesglucocorticoidinducedsuppressionofosteogenicdifferentiationbymodulatingpi3kaktrunx2signalingpathway
AT hanweichao epimedincalleviatesglucocorticoidinducedsuppressionofosteogenicdifferentiationbymodulatingpi3kaktrunx2signalingpathway
AT shaoyingying epimedincalleviatesglucocorticoidinducedsuppressionofosteogenicdifferentiationbymodulatingpi3kaktrunx2signalingpathway
AT chenminyi epimedincalleviatesglucocorticoidinducedsuppressionofosteogenicdifferentiationbymodulatingpi3kaktrunx2signalingpathway
AT zhangyusheng epimedincalleviatesglucocorticoidinducedsuppressionofosteogenicdifferentiationbymodulatingpi3kaktrunx2signalingpathway
AT heruirong epimedincalleviatesglucocorticoidinducedsuppressionofosteogenicdifferentiationbymodulatingpi3kaktrunx2signalingpathway
AT xiebaocheng epimedincalleviatesglucocorticoidinducedsuppressionofosteogenicdifferentiationbymodulatingpi3kaktrunx2signalingpathway